Combating Obesity: Trump’s Pharmaceutical Agreement Cuts Costs for Millions
- Trump administration secures $350-$149/month price cuts for GLP-1 drugs via TrumpRx.gov, expanding Medicare/Medicaid coverage to 40% of obese Americans. - Lilly and Novo Nordisk commit to aligning U.S. pricing with global benchmarks under MFN framework, part of broader cost-control measures including FDA incentives. - Policy faces $35B annual deficit risks from high demand, while pharma firms gain tariff certainty and access to 60M+ beneficiaries previously excluded. - Market reacts cautiously as Novo sh
President Donald Trump has announced a major deal with leading pharmaceutical companies
The administration highlighted that the deal requires
The financial impact of this policy is considerable. While the administration has pointed to patient savings, some critics caution that the broader coverage could add $35 billion per year to the national deficit due to the high demand for GLP-1 drugs, Fortune reported. CMS Administrator Mehmet Oz mentioned ongoing talks in October, highlighting the challenge of keeping treatments affordable while maintaining fiscal responsibility. At the same time, pharmaceutical firms gained certain assurances, such as stable tariffs and broader access for patients with obesity—a group that Medicare had previously not covered, according to Morningstar.
The agreements also cover additional medications beyond GLP-1 drugs. Lilly’s Zepbound and Novo’s oral Wegovy will be available for $346 and $150 per month, respectively, and insulin products will be priced at $35 per month through TrumpRx, as reported by Investors Business Daily. The companies are also investing further in U.S. manufacturing, with Lilly committing $27 billion and Novo $10 billion, according to Yahoo Finance. The market response was mixed: Novo Nordisk’s stock dropped by 3.5%, while Lilly’s saw a slight decline, reflecting investor uncertainty amid increased regulatory scrutiny, Investors Business Daily reported.
This policy change addresses a significant public health issue, as the CDC reports that 40% of American adults are obese, according to Investors Business Daily. By including weight-loss medications in Medicare, the Trump administration seeks to tackle chronic illnesses associated with obesity, such as diabetes and heart disease, while also working to lower prescription costs. However, the long-term effectiveness of this approach will depend on controlling Medicare expenses and ensuring all eligible patients have fair access, Axios reported.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin Updates: Growing Popularity of Stablecoins in Developing Economies Poses Challenges to Bitcoin’s Price Prospects
- Cathie Wood lowers Bitcoin's 2030 price target to $1.2M, citing stablecoins' dominance in emerging markets as a key factor. - Stablecoins like USDT/USDC now serve as primary payment tools in hyperinflationary regions, reshaping crypto's financial role. - Institutional forecasts adjust downward (Galaxy to $120K, JPMorgan at $170K) as stablecoins siphon $300B from traditional banking systems. - Venezuela, Argentina show stablecoins' adoption for cross-border transactions, with potential $1T extraction from

Zcash News Today: Zcash Bulls Surpass Shorts with $16M Profit Compared to $14.5M Deficit
- Zcash (ZEC) saw $16. 3M long gains vs. $14.5M short losses on Nov 7 amid 15% price surge. - Technical indicators show ZEC above key moving averages with RSI near overbought levels. - Market diverges from BTC/ETH ETF outflows as ZEC gains traction against macroeconomic headwinds. - Risks persist with open $14.5M short position and volatility threatening sustainability.

Supreme Court Weighs Trump’s Authority on Tariffs in Major Constitutional Dispute
- Trump admits U.S. consumers bear tariff costs, reversing prior claims foreign nations pay, as Supreme Court reviews IEEPA-based tariffs. - Businesses and states challenge tariffs as unconstitutional, arguing IEEPA doesn't authorize executive-imposed duties under the foreign commerce clause. - Courts have ruled against Trump's tariffs, but the administration plans to use alternative statutes like Section 232 to maintain trade policies if IEEPA is struck down. - Legal experts warn a IEEPA victory could ena

Vitalik Buterin's Newest ZK Breakthrough Triggers Fluctuations in the Crypto Market
- Vitalik Buterin's GKR protocol revolutionizes ZK proofs by reducing verification costs and hardware needs, enabling Ethereum's 2025 scalability goals. - ZK-based projects like ZKsync surged 150% in 2025 as Buterin endorsed upgrades achieving 15,000 TPS and near-zero gas fees. - Institutional adoption grows with Citibank and Deutsche Bank using ZKsync's Prividium, while Starknet and zkSync compete on throughput efficiency. - Investors prioritize ZK projects with strong GKR integration, ecosystem adoption,
